Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy
- 1 October 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (10), 4085-4091
- https://doi.org/10.1128/aac.00143-10
Abstract
Escherichia coli is the leading cause of bloodstream infections (BSIs) caused by Gram-negative bacteria. The increasing prevalence of antibiotic-resistant E. coli strains, particularly those producing extended-spectrum β-lactamases (ESBLs), increases the odds that empirically prescribed antimicrobial therapy for these infections will be inadequate, but the economic impact of this risk has not been fully evaluated. In the present retrospective 1-year analysis of 134 consecutive E. coli BSIs in our hospital, we explored the clinical and economic impacts of (i) inadequate initial antimicrobial treatment (IIAT) (i.e., empirical treatment with drugs to which the isolate had displayed in vitro resistance) of these infections and (ii) ESBL production by the bloodstream isolate. Cost data were obtained from the hospital accounting system. Compared with the 107 (79.8%) adequately treated patients, the 27 (20.1%) who received IIAT had a higher proportion of ESBL BSIs (74.0% versus 15.8%), longer (+6 days) and more costly (+EUR 4,322.00) post-BSI-onset hospital stays, and higher 21-day mortality rates (40.7% versus 5.6%). Compared with the 97 non-ESBL infections, the 37 (27.6%) ESBL BSIs were also associated with longer (+7 days) and more costly (+EUR 5,026.00) post-BSI-onset hospital stays and increased 21-day mortality (29.7% versus 6.1%). These findings confirm that the hospital costs and mortality associated with E. coli BSIs are significantly increased by ESBL production and by IIAT.This publication has 34 references indexed in Scilit:
- Extended-spectrum β-lactamase-producing organismsJournal of Hospital Infection, 2009
- The CTX-M β-lactamase pandemicCurrent Opinion in Microbiology, 2006
- Management of SepsisThe New England Journal of Medicine, 2006
- Resistance in gram-negative bacteria: EnterobacteriaceaeAmerican Journal of Infection Control, 2006
- Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2006
- The Relationship between Antimicrobial Resistance and Patient Outcomes: Mortality, Length of Hospital Stay, and Health Care CostsClinical Infectious Diseases, 2006
- Nosocomial Bacteremia Caused by Antibiotic‐Resistant Gram‐Negative Bacteria in Critically Ill Patients: Clinical Outcome and Length of HospitalizationClinical Infectious Diseases, 2002
- Epidemiology and Prognosis of Bacteremia: A 10-y Study in a Community HospitalScandinavian Journal of Infectious Diseases, 2002
- Extended-Spectrum -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on OutcomesClinical Infectious Diseases, 2001
- Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum -Lactamase Production in Klebsiella pneumoniae Isolates Causing BacteremiaClinical Infectious Diseases, 2000